Clinical trial
Phase I Study of Gimatecan in Patients With Myelodysplastic Syndromes
NCT00493571 · M.D. Anderson Cancer Center, Other · Completed
Key facts
| NCT number | NCT00493571 |
|---|---|
| Title | Phase I Study of Gimatecan in Patients With Myelodysplastic Syndromes |
| Official title | Phase I Study of Gimatecan in Patients With Myelodysplastic Syndromes |
| Lead sponsor | M.D. Anderson Cancer Center, Other |
| Collaborators | Novartis Industry |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Myelodysplastic Syndromes, MDS |
| Intervention type | Drug |
| Interventions | Gimatecan |
| Enrollment | 16 |
| Start date | Aug 1, 2007 |
| Primary completion | May 1, 2014 |
| Completion | May 1, 2014 |
| First posted | Jun 28, 2007 |
| Last update posted | May 13, 2015 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: